[Form 4] Arcturus Therapeutics Holdings Inc. Insider Trading Activity
Arcturus Therapeutics Holdings Inc. (ARCT) reporting person Andy Sassine, who is identified as both a Director and the Chief Financial Officer, executed a purchase under the companys 2020 Employee Stock Purchase Plan on 08/15/2025. The filing states 1,238 shares were purchased at an effective price of $16.558, which the filer explains was based on 85% of the closing price on that date. Following the reported transaction the filing lists 221,764 shares beneficially owned. The Form 4 is signed by an attorney-in-fact, Ilan Katz, dated 08/19/2025.
Arcturus Therapeutics Holdings Inc. (ARCT): la persona che ha effettuato la comunicazione, Andy Sassine, identificato sia come amministratore sia come Chief Financial Officer, ha acquistato azioni nell'ambito del 2020 Employee Stock Purchase Plan il 15/08/2025. La comunicazione indica l'acquisto di 1.238 azioni a un prezzo effettivo di $16.558, calcolato secondo quanto spiegato dal dichiarante come il 85% del prezzo di chiusura di quella data. Dopo l'operazione la segnalazione riporta la detenzione beneficiaria di 221.764 azioni. Il Modulo 4 è firmato per procura da Ilan Katz e datato 19/08/2025.
Arcturus Therapeutics Holdings Inc. (ARCT): la persona informante, Andy Sassine, identificado tanto como Director como Chief Financial Officer, realizó una compra según el 2020 Employee Stock Purchase Plan el 15/08/2025. La presentación indica la adquisición de 1.238 acciones a un precio efectivo de $16.558, que el declarante explica se basó en el 85% del precio de cierre de esa fecha. Tras la operación, la presentación señala una participación beneficiaria de 221.764 acciones. El Formulario 4 está firmado por apoderado, Ilan Katz, con fecha 19/08/2025.
Arcturus Therapeutics Holdings Inc. (ARCT)의 보고자 앤디 새신(Andy Sassine)은 이사이자 최고재무책임자(CFO)로 확인되며, 2020 Employee Stock Purchase Plan에 따라 2025년 08월 15일에 주식을 매수했습니다. 신고서에는 1,238주를 유효 가격 $16.558에 매수했으며, 신고인은 해당 가격이 그날의 종가의 85%를 기준으로 산정되었다고 설명하고 있습니다. 보고된 거래 이후 신고서에는 221,764주의 실질 보유가 기재되어 있습니다. Form 4는 대리인 Ilan Katz가 서명했으며 날짜는 2025년 08월 19일입니다.
Arcturus Therapeutics Holdings Inc. (ARCT) : la personne déclarée, Andy Sassine, identifié à la fois comme administrateur et directeur financier, a effectué un achat dans le cadre du 2020 Employee Stock Purchase Plan le 15/08/2025. Le dossier indique l'achat de 1 238 actions à un prix effectif de 16,558 $, que le déclarant précise avoir été calculé sur la base de 85 % du cours de clôture de cette date. Après l'opération, le dossier fait état d'une détention bénéficiaire de 221 764 actions. Le formulaire 4 est signé par un mandataire, Ilan Katz, et daté du 19/08/2025.
Arcturus Therapeutics Holdings Inc. (ARCT): Die meldepflichtige Person Andy Sassine, der sowohl als Direktor als auch als Chief Financial Officer ausgewiesen ist, tätigte am 15.08.2025 einen Kauf im Rahmen des 2020 Employee Stock Purchase Plan. Die Einreichung gibt an, dass 1.238 Aktien zu einem effektiven Preis von $16,558 erworben wurden, der laut Angabe des Meldenden auf 85% des Schlusskurses dieses Tages basiert. Nach der gemeldeten Transaktion werden 221.764 wirtschaftlich gehaltene Aktien ausgewiesen. Das Formular 4 ist von einem Bevollmächtigten, Ilan Katz, unterschrieben und datiert auf 19.08.2025.
- None.
- None.
Insights
TL;DR: Insider purchased shares through the ESPP at a stated 15% discount; transaction appears routine and non-material to valuation.
The filing documents a small-scale, plan-based purchase of 1,238 shares by the CFO/Director under the 2020 ESPP. The purchase price is noted as 85% of the closing price on 08/15/2025, consistent with typical ESPP discounts. The post-transaction beneficial ownership is reported as 221,764 shares. This is a compliance disclosure of insider activity rather than an operational or financial development.
TL;DR: Disclosure aligns with Section 16 reporting; transaction follows an established employee share plan and is procedurally standard.
The Form 4 correctly identifies the reporting persons roles and cites the ESPP as the transaction vehicle. The explanatory footnotes explicitly state the shares were purchased pursuant to the 2020 ESPP and priced at 85% of the issuers closing price. Signature by an attorney-in-fact is included with a date. No indications of atypical timing, derivative exercise, or other governance red flags are present in the text provided.
Arcturus Therapeutics Holdings Inc. (ARCT): la persona che ha effettuato la comunicazione, Andy Sassine, identificato sia come amministratore sia come Chief Financial Officer, ha acquistato azioni nell'ambito del 2020 Employee Stock Purchase Plan il 15/08/2025. La comunicazione indica l'acquisto di 1.238 azioni a un prezzo effettivo di $16.558, calcolato secondo quanto spiegato dal dichiarante come il 85% del prezzo di chiusura di quella data. Dopo l'operazione la segnalazione riporta la detenzione beneficiaria di 221.764 azioni. Il Modulo 4 è firmato per procura da Ilan Katz e datato 19/08/2025.
Arcturus Therapeutics Holdings Inc. (ARCT): la persona informante, Andy Sassine, identificado tanto como Director como Chief Financial Officer, realizó una compra según el 2020 Employee Stock Purchase Plan el 15/08/2025. La presentación indica la adquisición de 1.238 acciones a un precio efectivo de $16.558, que el declarante explica se basó en el 85% del precio de cierre de esa fecha. Tras la operación, la presentación señala una participación beneficiaria de 221.764 acciones. El Formulario 4 está firmado por apoderado, Ilan Katz, con fecha 19/08/2025.
Arcturus Therapeutics Holdings Inc. (ARCT)의 보고자 앤디 새신(Andy Sassine)은 이사이자 최고재무책임자(CFO)로 확인되며, 2020 Employee Stock Purchase Plan에 따라 2025년 08월 15일에 주식을 매수했습니다. 신고서에는 1,238주를 유효 가격 $16.558에 매수했으며, 신고인은 해당 가격이 그날의 종가의 85%를 기준으로 산정되었다고 설명하고 있습니다. 보고된 거래 이후 신고서에는 221,764주의 실질 보유가 기재되어 있습니다. Form 4는 대리인 Ilan Katz가 서명했으며 날짜는 2025년 08월 19일입니다.
Arcturus Therapeutics Holdings Inc. (ARCT) : la personne déclarée, Andy Sassine, identifié à la fois comme administrateur et directeur financier, a effectué un achat dans le cadre du 2020 Employee Stock Purchase Plan le 15/08/2025. Le dossier indique l'achat de 1 238 actions à un prix effectif de 16,558 $, que le déclarant précise avoir été calculé sur la base de 85 % du cours de clôture de cette date. Après l'opération, le dossier fait état d'une détention bénéficiaire de 221 764 actions. Le formulaire 4 est signé par un mandataire, Ilan Katz, et daté du 19/08/2025.
Arcturus Therapeutics Holdings Inc. (ARCT): Die meldepflichtige Person Andy Sassine, der sowohl als Direktor als auch als Chief Financial Officer ausgewiesen ist, tätigte am 15.08.2025 einen Kauf im Rahmen des 2020 Employee Stock Purchase Plan. Die Einreichung gibt an, dass 1.238 Aktien zu einem effektiven Preis von $16,558 erworben wurden, der laut Angabe des Meldenden auf 85% des Schlusskurses dieses Tages basiert. Nach der gemeldeten Transaktion werden 221.764 wirtschaftlich gehaltene Aktien ausgewiesen. Das Formular 4 ist von einem Bevollmächtigten, Ilan Katz, unterschrieben und datiert auf 19.08.2025.
